Quick Answer
Vaxcyte, Inc. reported Operating Income Loss of -$923.68 million for the year ending 2025.
- Vaxcyte, Inc. showed a decrease of -62.2% in Operating Income Loss from 2024 to 2025.
- This data is from Vaxcyte, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$13.94 million | Q2 2019: -$12.23 million | Q3 2019: -$12.14 million | Q4 2019: -$15.84 million | Q1 2020: -$27.60 million | Q2 2020: -$21.22 million | Q3 2020: -$21.31 million | Q4 2020: -$19.45 million | Q1 2021: -$23.14 million | Q2 2021: -$23.73 million | Q3 2021: -$26.95 million | Q1 2022: -$39.22 million | Q2 2022: -$47.89 million | Q3 2022: -$58.58 million | Q1 2023: -$71.19 million | Q2 2023: -$87.15 million | Q3 2023: -$113.03 million | Q1 2024: -$114.47 million | Q2 2024: -$152.98 million | Q3 2024: -$139.92 million | Q1 2025: -$180.79 million | Q2 2025: -$226.22 million | Q3 2025: -$242.38 million.
- Over the full 8 years of available data (2018 to 2025), Vaxcyte, Inc.'s Operating Income Loss has declined by 2,499.5%.
- Historical annual values: Fiscal year 2025: -$923.68 million | Fiscal year 2024: -$569.55 million | Fiscal year 2023: -$468.04 million | Fiscal year 2022: -$232.26 million | Fiscal year 2021: -$103.67 million | Fiscal year 2020: -$89.58 million | Fiscal year 2019: -$54.15 million | Fiscal year 2018: -$35.53 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: